PUMA BIOTECHNOLOGY INC
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| Item 5. | OTHER INFORMATION |
|---|
Trading Plans
During the fiscal quarter ended* March**31,* 2024, our directors and officers (as defined in Rule16a-1(f) under the Exchange Act) who adopted or terminated contracts, instructions, written plans or arrangements for the purchase or sale of our securities are set forth in the table below:
| Trading Arrangement | ||||||
| Name and Title | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares of Common Stock to be Sold | Expiration Date |
|---|---|---|---|---|---|---|
| Allison Dorval, Board Member | Adopt | March 6, 2024 | X | Up to 11,000 shares | June 30, 2024 | |
36
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.